ArticleScience (New York, N.Y.)2025
Human RPA is an essential telomerase processivity factor for maintaining telomeres.
Article in Science (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Fission yeast RPA-TERT-Tpz1TPP1 complex promotes telomere extension and suppresses telomere recombination.PLoS genetics · 2026Article
- How telomere attrition protects against cancer.Nature reviews. Genetics · 2026Review
- Fission yeast RPA-TERT-Tpz1bioRxiv : the preprint server for biology · 2026Article
- A homozygote mutation in RPA2 associated with bone marrow failure, immunodeficiency, and telomere biology disorder.European journal of human genetics : EJHG · 2026Article
- Article
- Structures of nucleotide-bound human telomerase at several steps of its telomeric DNA repeat addition cycle.Nature communications · 2026Article
- Whole exome sequencing identified two novel mutations ofFrontiers in cell and developmental biology · 2026Article
- Human RPA is an essential telomerase processivity factor for maintaining telomeres.Science (New York, N.Y.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Telomerase counteracts telomere shortening by repeatedly adding DNA repeats to chromosome ends. We identified the replication protein A (RPA) heterotrimer as a telomerase processivity factor critical for telomere maintenance. RPA stimulates telomerase processivity in vitro, and AlphaFold modeling predicts that RPA engages a telomerase surface distinct from the one bound by the shelterin subunit TPP1. Guided by these predictions, we engineered separation-of-function telomerase reverse transcriptase (TERT) mutants and found that the loss of RPA-mediated stimulation impairs telomere elongation, even when TPP1-POT1-mediated stimulation remains intact. Furthermore, short-telomere disease-associated TERT mutations reduce RPA-dependent telomerase stimulation, revealing a mechanistic link between impaired processivity and telomeropathies. Together, our findings establish human RPA as a key regulator of telomerase and offer molecular insights into telomere-related disease mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.